Abstracts tagged "clinical research and systemic lupus erythematosus (SLE)"

Abstract Number: 2632 • 2018 ACR/ARHP Annual Meeting
Rates and Predictors of Thirty-Day Readmission Among Patients Hospitalized for Systemic Lupus Erythematosus at a Single Tertiary Care Center
Stephen Mullis¹ and Dennis Ang², ¹Department of Internal Medicine, Section on Rheumatology and Immunology, Wake Forest School of Medicine, Winston Salem, NC, ²Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Systemic lupus erythematosus (SLE) has a 27.2% all-cause 30 day readmission rate, the 6th highest principle diagnosis among all medical conditions. The primary objective…
Abstract Number: 2625 • 2017 ACR/ARHP Annual Meeting
Predicting Flares in Patients with Stable Systemic Lupus Erythematosus
Jiacai Cho¹, Manjari Lahiri¹, Lay Kheng Teoh¹, Preeti Dhanasekaran^2,3, Pak Moon Peter Cheung¹ and Aisha Lateef¹, ¹Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ²National University of Singapore, singapore, Singapore, ³National University Hospital of Singapore, Singapore, Singapore
Background/Purpose: The course of systemic lupus erythematosus (SLE) varies with periods of quiescence punctuated by flares. Predicting exacerbations allows clinicians to select patients who need…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].